Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Pediatric Refractory Generalized Myasthenia Gravis
NCT03759366Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of eculizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Started Dec 2018; status: completed.
02
Drugs
eculizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03759366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759366.